AP
CLVS

AHL Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

AHL Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,707
Closed -$1.38M – 1402
2017
Q3 		$1.38M Buy
+16,707
New +$1.32M 0.02% 784
2016
Q1 		– Sell
-31,080
Closed -$1.09M – 850
2015
Q4 		$1.09M Buy
+31,080
New +$2M 0.08% 350

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AHL Partners's CLVS Position: Q4 2017 in Review

AHL Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 16,707 shares — an estimated $1.38M sold.

AHL Partners first reported a position in CLVS in Q4 2015 and held it in 2 quarters. The position peaked at $1.38M in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • AHL Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 16,707 Clovis Oncology, Inc. shares in Q4 2017, an estimated $1.38M.
  • AHL Partners first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 2 quarters.
  • AHL Partners's Clovis Oncology, Inc. position peaked at $1.38M in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.